Clinical Hours: Mon-Fri, 8AM - 3PM(905) 493-5700
1885 Glenanna Road, Suite 220, Pickering, ON, L1V 6R6
Autoimmune condition causing sudden, well-defined patches of hair loss on the scalp or body; treatment options include topical immunotherapy and corticosteroids.
Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks the hair follicles, resulting in sudden and often unpredictable hair loss. The condition is characterised by well-defined, smooth, round or oval patches of hair loss that can appear on the scalp, eyebrows, eyelashes, beard, or other areas of the body. Unlike conditions that cause permanent follicle destruction, alopecia areata generally leaves the follicles intact, meaning that hair regrowth is possible in many cases.
Alopecia areata affects approximately 2 percent of the global population at some point during their lifetime, making it one of the most common forms of non-scarring hair loss seen in dermatology practice. It can occur at any age, including in children, but onset is most frequently observed before the age of 30. The condition affects all sexes equally and has no predilection for any particular ethnic group.
The clinical course of alopecia areata is highly variable. In some individuals, one or two small patches of hair loss resolve spontaneously within a year without any treatment. In others, the condition is chronic and recurrent, with hair loss reappearing after periods of regrowth. A minority of patients progress to more extensive forms, including alopecia totalis, which involves complete loss of scalp hair, or alopecia universalis, which refers to complete loss of hair across the entire body.
Alopecia areata arises from an autoimmune mechanism in which T-lymphocytes cluster around and infiltrate the hair follicles, disrupting the normal cycle of hair growth. The follicle is forced prematurely into a resting state, causing the hair shaft to detach and fall out. The precise trigger for this immune misdirection has not been fully established, but a combination of genetic predisposition and environmental factors is believed to be responsible.
Recognised risk factors and associated conditions include:
The hallmark presentation of alopecia areata is one or more well-circumscribed, smooth patches of hair loss. The affected skin within these patches appears normal in colour and texture, without scaling, scarring, or inflammation visible to the naked eye. The scalp is most commonly involved, but any hair-bearing site may be affected.
Common clinical findings include:
The psychological impact of alopecia areata should not be underestimated. Hair loss, particularly when extensive or involving visible areas such as the eyebrows or eyelashes, can significantly affect self-esteem, social functioning, and quality of life. Anxiety and depression are more prevalent among individuals living with alopecia areata than in the general population.
Alopecia areata is most often diagnosed through a clinical examination by a dermatologist. The characteristic appearance of smooth, well-defined bald patches, combined with the presence of exclamation mark hairs and the absence of scarring or inflammation, is typically sufficient to establish the diagnosis without the need for additional investigations.
When the diagnosis is uncertain or the presentation is atypical, the following assessments may be undertaken:
There is currently no cure for alopecia areata, and no treatment is universally effective. The goal of management is to suppress the aberrant immune response to the hair follicle and stimulate regrowth. Treatment selection is guided by the extent of hair loss, the patient's age, the duration and pattern of disease, and individual response to prior therapies. Spontaneous remission occurs in a proportion of patients, particularly those with limited, early-onset disease.
Corticosteroids remain the most commonly employed treatment for alopecia areata. Intralesional corticosteroid injections, typically triamcinolone acetonide administered directly into the bald patches, are considered the first-line approach for limited scalp disease in adults. Results are generally seen within four to eight weeks of initiating treatment. Potent topical corticosteroids applied to affected areas represent an alternative, particularly in children or patients who are unable to tolerate injections. Systemic corticosteroids may be prescribed for rapidly progressive or extensive disease, though their use is generally limited to short courses given the risk of side effects associated with prolonged systemic exposure.
Topical immunotherapy with diphenylcyclopropenone (DPCP) or squaric acid dibutylester (SADBE) is among the most effective options for extensive alopecia areata. These agents are applied to the scalp in gradually increasing concentrations to induce a controlled allergic contact dermatitis, which is thought to redirect the immune response away from the hair follicles. Treatment is administered at regular intervals and may take several months before a response is observed. It is typically reserved for patients with greater than 50 percent scalp hair loss.
Minoxidil, applied topically in 2 or 5 percent formulations, is frequently used as an adjunctive therapy to promote hair regrowth. It does not address the underlying autoimmune process but may help to accelerate and consolidate regrowth achieved through other treatments.
JAK inhibitors, a newer class of targeted systemic therapy, have demonstrated significant efficacy in clinical trials for moderate to severe alopecia areata. Baricitinib and ritlecitinib have received regulatory approval in Canada for this indication and represent an important advance for patients with extensive or treatment-resistant disease. These agents work by blocking the Janus kinase signalling pathway involved in the autoimmune attack on hair follicles.
Additional therapeutic options include anthralin cream, topical calcineurin inhibitors, and phototherapy. Psychological support, including counselling and support groups, is an important component of comprehensive care, given the significant emotional burden associated with the condition. Cosmetic options such as wigs, hairpieces, and scalp micropigmentation may also be discussed with patients experiencing extensive or refractory hair loss.
A dermatologist should be consulted whenever unexpected hair loss is noticed, particularly if it appears suddenly, involves smooth bald patches, or is accompanied by nail changes. Early assessment allows an accurate diagnosis to be established and appropriate treatment to be initiated promptly, which may improve outcomes. Medical attention is also advisable if previously stable alopecia areata begins to worsen or spread, or if existing treatments are no longer producing an adequate response.
At the Centre for Medical and Surgical Dermatology, alopecia areata is assessed and managed by Dr. Maksym Breslavets using evidence-based approaches tailored to each patient's extent of hair loss, medical history, and treatment goals. A thorough evaluation is conducted to confirm the diagnosis, exclude other causes of hair loss, and develop an individualised management plan.
Your feedback helps us improve our condition information
A physician referral is required to access our medical services. Contact your primary care provider to begin the referral process.